Joycelynne Palmer, Ph.D.

[email protected]
626-256-4673, Ext 85266
Joycelynne Palmer PhD
Director and Professor, Division of Biostatistics
Research Area
Hematology and Hematopoietic Cell Transplantation
Clinical Trials Design
Translational Research
Precision Medicine
Appointments
Professor, Department of Computational and Quantitative Medicine
Research Teams
Biostatistics
Computational and Quantitative Medicine

Location

Education & Experience

Degrees

  • 2004, Ph.D., Preventive Medicine: Epidemiology, University of Southern California, Los Angeles, California

  • 1995, M.S., Biostatistics and Epidemiology, University of Southern California, Los Angeles, California

  • 1993, B.S., Biology, University of California -Irvine

  • Irvine, California

  • 1993, B.A., Psychology, University of California -Irvine

  • Irvine, California

Professional Experience

  • 2019-Present, Director, Division of Biostatistics, Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, CA

  • 2019-present, Director, Biostatistics and Mathematical Oncology Core, Cancer Center Support Grant

  • 2017-present, Biostatistics Core Director, Hematologic Malignancies and Stem Cell Transplantation Institute

  • 2016-present, Biostatistics Instructor: American Society for Transplantation and Cellular Therapy, Clinical Research Training Course

  • 2007-2016, Biostatistics Instructor, Course: Methodology in Clinical Investigation, Clinical Investigation Training Program, City of Hope, Duarte, California

  • 2006-2015, Adjunct Professor, Course: Introduction to Biostatistics, Claremont Graduate University, School of Information Systems and Technology, Claremont, California

  • 2005-2017, Biostatistics Section Head, Hematologic Malignancies and HCT, Division of Biostatistics, City of Hope, Duarte, California

  • 2002-2005, Lead Systems Analyst/Clinical Research Operations Manager/Senior Biostatistician, Department of Information Sciences, City of Hope, Duarte, California

Publications

Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008 Aug 1; 112(3):903-9. PubMed PMID: 18519812; PubMed Central PMCID: PMC2481551.
 
Stein AS, Palmer JM, O'Donnell MR, Kogut NM, Spielberger RT, Slovak ML, Tsai NC, Senitzer D, Snyder DS, Thomas SH, Forman SJ. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2009 Nov;15(11): 1407-14. PubMed PMID: 19822300; PubMed Central PMCID: PMC2795637.
 
Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AV. Autologous transplantation for transformed non­-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. Biol Blood Marrow Transplant. 2014; 20(12): 2072-5. PMID: 25079874.
 
Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Annuals of Oncology. 2018; 29(3): 724-730. PMCID: PMC5889038.
 
Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AV, Senitzer D, Forman SJ. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010 Feb 4;115(5):1098-105. PubMed PMID: 19965688; PubMed Central PMCID: PMC2817636.
 
Khaled SK, Palmer JM, Stiller T, Senitzer D, Maegawa R, Rodriguez R, Parker PM, Nademanee A, Cai JL, Snyder DS, Karanes C, Osorio E, Thomas SH, Forman SJ, Nakamura R. A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-­donor PBSC transplant. Bone Marrow Transplantation. 2013 Feb;48(2):278-83. PubMed PMID: 23000644; PubMed Central PMCID: PMC3566319.
 
Ali H, Palmer J, Eroglu Z, Stiller T, Thomas SH, Kha led S, Shayani S, Parker P, Forman SJ, Nakamura R. Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplantation. 2015; 50(2): 307-309. PubMed PMID: 25365064; PMCID: PMC4318766.
 
Kha led SK, Palmer JM, Herzog J, Stiller T, Tsai NC, Senitzer D, Liu X, Thomas SH, Shayani S, Weitzel J, Forman SJ, Nakamura R. Influence of absorption, distribution, metabolism, and excretion genomic variants on tacrolimus/sirolimus blood levels and graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22(2): 268-76. PubMed PMID: 26325438; PMCID PMC4716887.
 
Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Kha led S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J. Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed/refractory acute leukemia. Biol Blood Marrow Transplant 23(4): 618-624, 2017. PMCID: PMC5382014.
 
Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O'Donnell M, Stein AS, Marcucci G, Forman S, Pullarkat V. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology 92(9): 858-865, 2017. PMID: 28494518.
 
Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase 1/11 trial of the oral regimen ixazomib, Pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia, 2017. PMCID: PMC6005710
 
Caserta E, Chea J, Minnix M, Viola D, Vonderfecht S, Yazaki P, Crow D, Khalife J, Sanchez JF, Palmer JM, Hui S, Carlesso N, Keats J, Kim Y, Buettner R, Marcucci G, Rosen S, Shively J, Colcher D, Krishnan A, Pichiorri F. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood 131(7): 741-745, 2018. PMCID: PMC5814935.